Postdoctoral Research Associate in Radiochemistry
We are seeking a talented, highly skilled and motivated Postdoctoral Research Associate to work on the design, synthesis and characterisation of novel small molecule radiotracers for cancer imaging. This is an exciting opportunity to join the Molecular Imaging Lab at King’s College London (www.witneylab.com), a vibrant multidisciplinary research group within one of the premier biomedical imaging centres in Europe. The post holder will have access to new state-of-the-art organic and radiochemistry facilities and a vast array of small animal and clinical imaging modalities, further supported by the cutting-edge equipment and core facilities at King’s. Our Group has a track record of research excellence, substantial grant funding, and awards (e.g. World Molecular Imaging Congress’ Young Investigator of the Year Award, CME postdoctoral Fellowship). We are dedicated to supporting the successful candidate’s career through assistance with Fellowship applications, networking events, and attendance at international conferences.
The successful candidate will have experience in synthetic chemistry, be self-motivated, able to work independently, and will have excellent written and verbal communication skills. The applicant must have a Ph.D. in organic chemistry, medicinal chemistry or radiochemistry. They should be able to demonstrate a proven track record of scientific publications as first author in their chosen field. Applicants with radiochemistry experience (fluorine-18 preferred) and a keen interest in chemical biology and multidisciplinary research are especially encouraged to apply. Hands-on training will be given to the successful candidate.
Project description and vision
Therapy resistance is one of the biggest problems currently facing clinical oncology. Currently, there is no satisfactory way to identify patients that will and those that will not respond to treatment. Positron emission tomography (PET) imaging offers a potential solution to this clinical problem through the non-invasive assessment of molecular processes that underpin therapy-resistance. The identification of cancer patients that are refractory to treatment will allow the selection of second-line therapies that have the potential to improve patient response and survival. Employing a combination of innovative preclinical imaging strategies, we are developing new tools to non-invasively assess the mechanisms that tumour cells employ to resist treatment, following substantial investment by the Wellcome Trust (£2.4m). The successful candidate will develop new chemistry and novel fluorine-18 labelled radiotracers for imaging with positron emission tomography (PET) to support this programme of research. In collaboration with the new GMP radiochemistry facility at KCL (the PEARL), we will translate these novel imaging methods to the clinic.